These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 17130820

  • 21. Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and treatment.
    Cochat P, Hulton SA, Acquaviva C, Danpure CJ, Daudon M, De Marchi M, Fargue S, Groothoff J, Harambat J, Hoppe B, Jamieson NV, Kemper MJ, Mandrile G, Marangella M, Picca S, Rumsby G, Salido E, Straub M, van Woerden CS, OxalEurope.
    Nephrol Dial Transplant; 2012 May; 27(5):1729-36. PubMed ID: 22547750
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Glyoxylate synthesis, and its modulation and influence on oxalate synthesis.
    Holmes RP, Assimos DG.
    J Urol; 1998 Nov; 160(5):1617-24. PubMed ID: 9783918
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Glyoxylate reductase: Definitive identification in human liver mitochondria, its importance for the compartment-specific detoxification of glyoxylate.
    Garrelfs SF, Chornyi S, Te Brinke H, Ruiter J, Groothoff J, Wanders RJA.
    J Inherit Metab Dis; 2024 Mar; 47(2):280-288. PubMed ID: 38200664
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Endogenous Oxalate Production in Primary Hyperoxaluria Type 1 Patients.
    Garrelfs SF, van Harskamp D, Peters-Sengers H, van den Akker CHP, Wanders RJA, Wijburg FA, van Goudoever JB, Groothoff JW, Schierbeek H, Oosterveld MJS.
    J Am Soc Nephrol; 2021 Dec 01; 32(12):3175-3186. PubMed ID: 34686543
    [Abstract] [Full Text] [Related]

  • 30. Hydroxyproline Metabolism and Oxalate Synthesis in Primary Hyperoxaluria.
    Fargue S, Milliner DS, Knight J, Olson JB, Lowther WT, Holmes RP.
    J Am Soc Nephrol; 2018 Jun 01; 29(6):1615-1623. PubMed ID: 29588429
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Potential mechanisms of marked hyperoxaluria not due to primary hyperoxaluria I or II.
    Monico CG, Persson M, Ford GC, Rumsby G, Milliner DS.
    Kidney Int; 2002 Aug 01; 62(2):392-400. PubMed ID: 12110000
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Improving Treatment Options for Primary Hyperoxaluria.
    Hoppe B, Martin-Higueras C.
    Drugs; 2022 Jul 01; 82(10):1077-1094. PubMed ID: 35779234
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Treatment of the primary hyperoxalurias: a new chapter.
    Milliner D.
    Kidney Int; 2006 Oct 01; 70(7):1198-200. PubMed ID: 16988727
    [Abstract] [Full Text] [Related]

  • 38. [Primary hyperoxaluria].
    Cochat P, Fargue S, Bacchetta J, Bertholet-Thomas A, Sabot JF, Harambat J.
    Nephrol Ther; 2011 Jul 01; 7(4):249-59. PubMed ID: 21636340
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Epigenomic and transcriptional profiling identifies impaired glyoxylate detoxification in NAFLD as a risk factor for hyperoxaluria.
    Gianmoena K, Gasparoni N, Jashari A, Gabrys P, Grgas K, Ghallab A, Nordström K, Gasparoni G, Reinders J, Edlund K, Godoy P, Schriewer A, Hayen H, Hudert CA, Damm G, Seehofer D, Weiss TS, Boor P, Anders HJ, Motrapu M, Jansen P, Schiergens TS, Falk-Paulsen M, Rosenstiel P, Lisowski C, Salido E, Marchan R, Walter J, Hengstler JG, Cadenas C.
    Cell Rep; 2021 Aug 24; 36(8):109526. PubMed ID: 34433051
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.